European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment.
Loading...
Embargo End Date
ICR Authors
Authors
Lee, GA
Aktaa, S
Baker, E
Gale, CP
Yaseen, IF
Gulati, G
Asteggiano, R
Szmit, S
Cohen-Solal, A
Abdin, A
Jurczak, W
Garrido Lopez, P
Sverdlov, AL
Tocchetti, CG
Barac, A
Parrini, I
Zamorano, P
Iakobishvili, Z
Pudil, R
Badimon, L
Kirby, AM
Blaes, AH
Farmakis, D
Curigliano, G
Stephens, R
Lyon, AR
Lopez-Fernandez, T
Aktaa, S
Baker, E
Gale, CP
Yaseen, IF
Gulati, G
Asteggiano, R
Szmit, S
Cohen-Solal, A
Abdin, A
Jurczak, W
Garrido Lopez, P
Sverdlov, AL
Tocchetti, CG
Barac, A
Parrini, I
Zamorano, P
Iakobishvili, Z
Pudil, R
Badimon, L
Kirby, AM
Blaes, AH
Farmakis, D
Curigliano, G
Stephens, R
Lyon, AR
Lopez-Fernandez, T
Document Type
Journal Article
Date
2022-12-13
Date Accepted
2022-10-21
Abstract
AIMS: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. METHODS AND RESULTS: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. CONCLUSION: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.
Citation
European Heart Journal - Quality of Care and Clinical Outcomes, 2022, 9 (1), pp. 1 - 7
Source Title
European Heart Journal - Quality of Care and Clinical Outcomes
Publisher
OXFORD UNIV PRESS
ISSN
2058-5225
eISSN
2058-1742
2058-1742
2058-1742